
  
    
      
        Background_NNP
        Localization_NNP of_IN leukocytes_NNS to_TO tissue_NN sites_NNS is_VBZ a_DT critical_JJ
        part_NN of_IN infectious_JJ ,_, inflammatory_JJ or_CC immune_JJ responses_NNS [_NN 1_CD 2_CD
        ]_NN ._. Emigration_NN of_IN leukocytes_NNS from_IN blood_NN into_IN tissue_NN
        requires_VBZ a_DT complex_JJ array_NN of_IN molecular_JJ and_CC cellular_JJ events_NNS
        between_IN the_DT flowing_VBG leukocyte_NN and_CC endothelium_NN lining_VBG the_DT
        blood_NN vessel_NN wall_NN ._. Development_NNP of_IN the_DT parallel_JJ plate_NN flow_NN
        chamber_NN that_WDT simulates_VBZ the_DT conditions_NNS of_IN physiologic_JJ flow_NN
        has_VBZ been_VBN an_DT important_JJ tool_NN for_IN dissecting_VBG the_DT molecular_JJ
        events_NNS occurring_VBG between_IN flowing_VBG leukocytes_NNS and_CC endothelium_NN
        [_NN 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD ]_NN ._.
        One_CD of_IN the_DT first_JJ parallel_JJ plate_NN flow_NN chamber_NN described_VBD
        to_TO study_VB neutrophil_NN adhesion_NN to_TO endothelium_NN was_VBD described_VBN
        in_IN 1987_CD by_IN Lawrence_NNP et_CC al_NN [_NN 7_CD ]_NN ._. Initially_RB ,_, several_JJ
        investigators_NNS produced_VBD chambers_NNS identical_JJ to_TO or_CC very_RB
        similar_JJ to_TO this_DT design_NN ,_, and_CC over_IN the_DT years_NNS this_DT initial_JJ
        design_NN has_VBZ been_VBN the_DT most_RBS widely_RB used_VBN [_NN 8_CD ]_NN ._. This_DT design_NN
        allowed_VBN for_IN study_NN of_IN leukocyte-endothelial_JJ interaction_NN from_IN
        a_DT top-down_JJ view_NN and_CC under_IN laminar_NN flow_NN that_WDT occurs_VBZ in_IN the_DT
        post-capillary_JJ venules_NNS ,_, the_DT physiologically_RB relevant_JJ site_NN
        for_IN most_JJS leukocyte_NN emigration_NN ._. Design_NN modifications_NNS have_VBP
        also_RB been_VBN made_VBN that_WDT allow_VBP for_IN pulsatile_NN flow_NN ,_, a_DT simulation_NN
        of_IN larger_JJR vessel_NN blood_NN flow_NN ,_, as_RB well_RB as_IN lateral_NN viewing_VBG
        that_WDT can_MD give_VB more_RBR detailed_JJ morphologic_JJ information_NN [_NN 11_CD 12_CD
        ]_NN ._. Agarose-cast_NNP vessels_NNS and_CC glass_NN capillary_JJ flow_NN chambers_NNS
        have_VBP also_RB been_VBN described_VBN [_NN 12_CD 14_CD 15_CD ]_NN ._. In_IN spite_NN of_IN the_DT
        large_JJ number_NN of_IN scientifically_RB important_JJ observations_NNS that_WDT
        have_VBP been_VBN made_VBN with_IN this_DT technology_NN ,_, these_DT chambers_NNS have_VBP at_IN
        least_JJS two_CD weaknesses_NNS :_: 1_LS )_) Significant_JJ numbers_NNS of_IN leukocytes_NNS
        are_VBP required_VBN ,_, making_VBG study_NN of_IN rare_JJ leukocyte_NN populations_NNS
        such_JJ as_IN basophils_NNS or_CC some_DT lymphocyte_NN subsets_NNS difficult_JJ ,_, and_CC
        2_LS )_) Large_JJ amounts_NNS of_IN inhibitors_NNS are_VBP needed_VBN to_TO study_VB their_PRP$
        effects_NNS ,_, limiting_VBG the_DT use_NN of_IN the_DT parallel_JJ plate_NN as_IN a_DT tool_NN
        for_IN drug_NN discovery_NN ._. More_RBR recently_RB ,_, a_DT commercially-produced_JJ
        flow_NN chamber_NN (_( GlycoTech_NNP ,_, Rockville_NNP ,_, MD_NNP )_) is_VBZ available_JJ that_WDT
        potentially_RB overcomes_VBZ these_DT weaknesses_NNS ,_, since_IN it_PRP is_VBZ
        considerably_RB smaller_JJR than_IN the_DT initial_JJ chamber_NN produced_VBN by_IN
        Lawrence_NNP et_CC al_NN [_NN 7_CD ]_NN ._.
        In_IN this_DT study_NN we_PRP were_VBD interested_JJ in_IN comparing_VBG the_DT
        reagent_NN and_CC cellular_JJ requirements_NNS of_IN the_DT newer_JJR GlycoTech_NNP
        chamber_NN with_IN different_JJ modifications_NNS to_TO the_DT chamber_NN
        described_VBN by_IN Lawrence_NNP [_NN 7_CD ]_NN ._. In_IN addition_NN ,_, we_PRP wished_VBD to_TO
        test_VB modifications_NNS in_IN tubing_VBG and_CC pumps_NNS in_IN order_NN to_TO optimize_NN
        the_DT architecture_NN of_IN the_DT flow_NN chambers_NNS for_IN study_NN of_IN rare_JJ
        leukocyte_NN populations_NNS and_CC small_JJ molecule_NN antagonists_NNS ._.
      
      
        Results_NNS and_CC Discussion_NNP
        
          Comparison_NNP of_IN volume_NN and_CC cellular_JJ requirements_NNS for_IN
          different_JJ parallel_JJ plate_NN flow_NN chamber_NN
          configurations_NNS
          We_PRP empirically_RB determined_VBD the_DT volume_NN needs_VBZ for_IN each_DT
          chamber_NN design_NN and_CC modification_NN by_IN measuring_VBG the_DT volume_NN
          needed_VBN to_TO fill_VB the_DT chamber_NN ,_, tubing_VBG ,_, and_CC other_JJ components_NNS ._.
          A_DT comparison_NN of_IN the_DT volume_NN and_CC cellular_JJ requirements_NNS for_IN
          each_DT parallel_JJ plate_NN flow_NN chamber_NN configuration_NN is_VBZ
          summarized_VBD in_IN Table_NNP 1_CD ._. We_PRP compared_VBD the_DT potential_JJ
          capabilities_NNS of_IN three_CD chamber_NN designs_NNS ,_, the_DT original_JJ
          chamber_NN designed_VBN by_IN Lawrence_NNP [_NN 7_CD ]_NN (_( "_'' classic_JJ "_'' chamber_NN )_) ,_,
          the_DT single_JJ pass_NN GlycoTech_NNP design_NN (_( Product_NN 31_CD -_: 001_CD )_) ,_, and_CC a_DT
          recirculating_VBG design_NN using_VBG the_DT GlycoTech_NNP chamber_NN (_( Fig_NNP ._.
          1_LS )_) ._. In_IN order_NN to_TO assess_VB the_DT potential_JJ cellular_JJ
          requirements_NNS for_IN an_DT experiment_NN ,_, we_PRP assumed_VBD usage_NN of_IN
          standard_JJ isolation_NN techniques_NNS of_IN blood_NN leukocytes_NNS with_IN
          venipucture_NN volumes_NNS that_IN we_PRP and_CC others_NNS employ_VBP for_IN these_DT
          experiments_NNS [_NN 6_CD 13_CD 16_CD 17_CD ]_NN ,_, which_WDT are_VBP 30_CD ml_NN ,_, 100_CD ml_NN ,_, and_CC
          100_CD ml_NN for_IN neutrophils_NNS ,_, eosinophils_NNS ,_, and_CC basophils_NNS ,_,
          respectively_RB ._. Neutrophils_NNP ,_, eosinophils_NNS and_CC basophils_NNS are_VBP
          at_IN concentration_NN ranges_NNS of_IN 1800_CD -_: 7000_CD /_NN μl_NN ,_, 0_CD -_: 300_CD /_NN μl_NN ,_, and_CC
          0_CD -_: 100_CD /_NN μl_NN ,_, respectively_RB ,_, in_IN normal_JJ adults_NNS [_NN 18_CD ]_NN ._.
          Accordingly_RB ,_, the_DT total_JJ cells_NNS yielded_VBD from_IN these_DT
          preparations_NNS are_VBP typically_RB 3_CD ×_NN 10_CD 7_CD ,_, 2_CD ×_NN 10_CD 6_CD ,_, and_CC 6_CD ×_NN 10_CD
          5_CD leukocytes_NNS per_IN preparation_NN of_IN neutrophils_NNS ,_, eosinophils_NNS ,_,
          or_CC basophils_NNS ,_, respectively_RB ._. Furthermore_RB ,_, one_CD of_IN the_DT
          disadvantages_NNS of_IN the_DT GlycoTech_NNP chamber_NN is_VBZ that_IN it_PRP does_VBZ
          not_RB have_VB injection_NN ports_NNS for_IN studying_VBG the_DT rapid_JJ effects_NNS
          of_IN soluble_JJ substances_NNS on_IN leukocyte_NN behavior_NN ._. To_TO
          circumvent_VB this_DT problem_NN ,_, we_PRP added_VBD a_DT stopcock_NN valve_NN to_TO
          allow_VB for_IN reagent_NN injection_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ._. This_DT design_NN with_IN
          the_DT stopcock_NN was_VBD used_VBN in_IN the_DT calculations_NNS below_IN ._.
          We_PRP next_RB calculated_VBD the_DT number_NN of_IN cells_NNS that_WDT would_MD be_VB
          required_VBN for_IN the_DT two_CD most_RBS common_JJ usages_NNS of_IN a_DT parallel_JJ
          plate_NN flow_NN chamber_NN ;_: 1_LS )_) a_DT standard_JJ shear_NN curve_NN (_( i_NNP ._. e_SYM ._.
          number_NN of_IN cells_NNS attached_VBN to_TO a_DT surface_NN versus_CC a_DT range_NN of_IN
          shear_NN forces_NNS )_) and_CC 2_LS )_) a_DT constant_JJ shear_NN perfusion_NN
          experiment_NN in_IN which_WDT the_DT number_NN of_IN attached_VBN cells_NNS is_VBZ
          determined_VBN over_IN a_DT 10_CD min_NN period_NN ._. In_IN order_NN to_TO obtain_VB a_DT
          significant_JJ number_NN of_IN attached_VBN cells_NNS during_IN the_DT
          experiment_NN ,_, we_PRP assumed_VBD that_IN cells_NNS would_MD be_VB used_VBN at_IN a_DT
          concentration_NN of_IN 1_CD ×_NN 10_CD 6_CD /_NN ml_NN as_IN is_VBZ commonly_RB practiced_VBN ._.
          Using_VBG standard_JJ tubing_VBG (_( 0_CD ._. 062_CD "_'' I_PRP ._. D_NNP ,_, internal_JJ diameter_NN )_)
          there_EX are_VBP significant_JJ differences_NNS in_IN the_DT volume_NN and_CC cells_NNS
          needed_VBN for_IN an_DT experiment_NN using_VBG the_DT three_CD chamber_NN
          configurations_NNS ._. The_DT classic_JJ and_CC single_JJ pass_NN GlycoTech_NNP
          chamber_NN needed_VBD 1_CD ×_NN 10_CD 7_CD versus_CC 2_CD ._. 4_CD ×_NN 10_CD 6_CD cells_NNS to_TO produce_VB
          a_DT shear_NN curve_NN ._. One_CD of_IN the_DT weaknesses_NNS of_IN the_DT
          re-circulating_JJ parallel_JJ plate_NN using_VBG a_DT Harvard_NNP Apparatus_NNP
          peristaltic_JJ pump_NN is_VBZ that_IN the_DT pump_NN rate_NN cannot_NN be_VB changed_VBN
          without_IN stopping_VBG the_DT pump_NN ._. Thus_RB ,_, the_DT reciculating_VBG design_NN
          in_IN Fig_NNP ._. 1_LS Dcannot_NNP be_VB used_VBN to_TO produce_VB shear_NN curves_NNS ._.
          Likewise_RB ,_, there_EX are_VBP significant_JJ differences_NNS in_IN the_DT
          cellular_JJ and_CC volume_NN needs_VBZ for_IN a_DT constant_JJ shear_NN experiment_NN
          between_IN the_DT classic_JJ ,_, single_JJ pass_NN GlycoTech_NNP ,_, and_CC
          recirculation_NN chambers_NNS (_( 1_CD ._. 2_LS ×_NN 10_CD 7_CD ,_, 2_CD ._. 2_CD ×_NN 10_CD 6_CD ,_, and_CC 4_CD ._. 1_CD ×_NN
          10_CD 6_CD cells_NNS respectively_RB )_) ._.
          Tubing_NNP diameter_NN may_MD also_RB dramatically_RB impact_VB the_DT total_JJ
          volume_NN and_CC cells_NNS required_VBN per_IN experiment_NN ._. We_PRP examined_VBD the_DT
          dead_JJ volume_NN and_CC total_JJ cellular_JJ requirements_NNS using_VBG the_DT
          standard_JJ 0_CD ._. 062_CD "_'' ID_NNP as_RB well_RB as_IN 0_CD ._. 02_CD "_'' ID_NNP and_CC 0_CD ._. 01_CD "_'' ID_NNP
          tubing_VBG ._. We_PRP did_VBD not_RB use_VB ID_NNP less_JJR than_IN 0_CD ._. 01_CD "_'' ID_NNP (_( 254_CD μm_NN )_)
          since_IN neutrophil_NN diameters_NNS vary_VBP from_IN 7_CD -_: 15_CD μm_NN ,_, and_CC we_PRP
          wished_VBD to_TO have_VB ample_JJ diameter_NN for_IN cell_NN passage_NN ._.
          Furthermore_RB ,_, post-capillary_JJ venules_NNS ,_, the_DT physiologically_RB
          relevant_JJ site_NN of_IN leukocyte_NN extravasation_NN ,_, have_VBP diameters_NNS
          of_IN 30_CD -_: 80_CD μm_NN [_NN 19_CD ]_NN ._. Finally_RB ,_, technical_JJ issues_NNS occurred_VBD
          with_IN 0_CD ._. 01_CD "_'' ID_NNP (_( see_VB below_IN )_) ._. Narrower_NNP internal_JJ tubing_VBG
          diameters_NNS resulted_VBD in_IN a_DT 66_CD -_: 83_CD %_NN reduction_NN in_IN cell_NN or_CC
          volume_NN requirements_NNS ._. Therefore_RB ,_, an_DT increase_NN in_IN number_NN of_IN
          experiments_NNS could_MD be_VB performed_VBN per_IN cell_NN preparation_NN ,_, and_CC
          the_DT need_NN for_IN reagents_NNS whether_IN they_PRP be_VB soluble_JJ factors_NNS ,_,
          monoclonal_NN antibodies_NNS ,_, or_CC small_JJ molecule_NN antagonists_NNS
          would_MD also_RB be_VB reduced_VBN proportionately_RB with_IN smaller_JJR
          volumes_NNS ._.
          Reduction_NNP in_IN the_DT proportion_NN of_IN dead_JJ volume_NN to_TO total_VB
          volume_NN per_IN experiment_NN also_RB contributes_VBZ to_TO the_DT reduction_NN
          in_IN cells_NNS and_CC reagents_NNS ._. The_DT dead_JJ volume_NN is_VBZ dramatically_RB
          reduced_VBN with_IN the_DT reduction_NN of_IN the_DT internal_JJ diameter_NN of_IN
          the_DT tubing_VBG regardless_RB of_IN chamber_NN design_NN (_( Table_NNP 1_LS )_) ._. One_CD of_IN
          the_DT principal_JJ reasons_NNS of_IN regeant_NN and_CC cell_NN waste_NN is_VBZ the_DT
          dead_JJ volume_NN ,_, since_IN dead_JJ volume_NN constitutes_VBZ from_IN 6_CD -_: 100_CD %_NN of_IN
          the_DT total_JJ volume_NN per_IN experiment_NN (_( depending_VBG on_IN the_DT chamber_NN
          configuration_NN ,_, see_VB Table_NNP 1_LS )_) ._. Since_IN the_DT dead_JJ volume_NN is_VBZ
          reduced_VBN in_IN addition_NN to_TO the_DT total_JJ volume_NN with_IN either_DT the_DT
          single_JJ pass_NN or_CC recirculating_VBG GlycoTech_NNP chamber_NN design_NN in_IN
          comparison_NN to_TO the_DT classic_JJ chamber_NN ,_, there_EX is_VBZ significant_JJ
          reduction_NN in_IN the_DT amount_NN of_IN reagent_NN or_CC cells_NNS needed_VBN for_IN
          each_DT experiment_NN ._.
          The_DT length_NN of_IN time_NN of_IN an_DT experiment_NN is_VBZ also_RB important_JJ
          consideration_NN in_IN the_DT comparison_NN of_IN the_DT single_JJ pass_NN
          GlycoTech_NNP to_TO recirculating_VBG design_NN in_IN terms_NNS of_IN reagent_NN
          use_NN ._. The_DT GlycoTech_NNP chamber_NN requires_VBZ 66_CD -_: 83_CD %_NN less_JJR cells_NNS or_CC
          reagents_NNS in_IN comparison_NN to_TO the_DT GlycoTech_NNP single_JJ pass_NN in_IN a_DT
          10_CD min_NN constant_JJ shear_NN experiment_NN ._. However_RB ,_, if_IN 3_CD min_NN
          experiments_NNS with_IN 0_CD ._. 062_CD "_'' ID_NNP tubing_VBG were_VBD performed_VBN ,_, which_WDT
          have_VBP been_VBN reported_VBN [_NN 13_CD ]_NN ,_, then_RB the_DT recirculating_VBG
          chamber_NN requires_VBZ 15_CD %_NN more_RBR total_JJ volume_NN than_IN the_DT classic_JJ
          chamber_NN and_CC 639_CD %_NN more_JJR volume_NN than_IN the_DT single_JJ pass_NN
          GlycoTech_NNP chamber_NN ._. Thus_RB ,_, since_IN the_DT single_JJ pass_NN chamber_NN
          requires_VBZ increasing_VBG reagents_NNS with_IN time_NN ,_, the_DT requirements_NNS
          may_MD be_VB smaller_JJR with_IN the_DT re-circulating_JJ configuration_NN
          depending_VBG on_IN the_DT length_NN of_IN experiment_NN ._.
        
        
          Validation_NNP
          To_TO verify_VB the_DT performance_NN of_IN the_DT single_JJ pass_NN GlycoTech_NNP
          and_CC re-circulating_JJ flow_NN chamber_NN ,_, measurements_NNS of_IN
          leukocyte_NN adhesion_NN made_VBN with_IN these_DT chambers_NNS were_VBD compared_VBN
          to_TO those_DT of_IN the_DT classic_JJ chamber_NN ._. Several_JJ standard_JJ
          measurements_NNS can_MD be_VB made_VBN with_IN a_DT parallel_JJ plate_NN flow_NN
          chamber_NN ,_, including_VBG the_DT total_JJ number_NN of_IN attached_VBN cells_NNS ,_,
          the_DT number_NN of_IN rolling_VBG cells_NNS ,_, the_DT number_NN of_IN firmly_RB
          arrested_VBN cells_NNS ,_, and_CC the_DT rolling_VBG velocity_NN ._. We_PRP performed_VBD
          experiments_NNS that_WDT measured_VBD each_DT of_IN these_DT quantities_NNS and_CC
          compared_VBD the_DT precision_NN of_IN the_DT measurements_NNS among_IN each_DT
          parallel_JJ plate_NN flow_NN chamber_NN design_NN ._.
          We_PRP first_RB examined_VBD the_DT number_NN of_IN flowing_VBG neutrophils_NNS
          that_WDT attached_VBD to_TO EC_NNP monolayers_NNS in_IN both_DT the_DT classic_JJ and_CC
          GlycoTech_NNP single_JJ pass_NN flow_NN chambers_NNS over_IN a_DT range_NN of_IN shear_NN
          stress_NN ._. (_( Fig_NNP 2_CD A_DT )_) The_DT range_NN of_IN shear_NN stress_NN was_VBD chosen_VBN to_TO
          recapitulate_NN those_DT in_IN the_DT post-capillary_JJ venules_NNS (_( 0_CD ._. 5_LS -_: 5_CD
          dynes_NNS /_NN cm_NN 2_LS )_) ._. No_DT statistically_RB significant_JJ differences_NNS
          were_VBD seen_VBN in_IN terms_NNS of_IN the_DT number_NN of_IN cells_NNS that_WDT attached_VBD
          to_TO activated_VBN endothelium_NN over_IN the_DT range_NN of_IN shear_NN stresses_VBZ
          examined_VBN ._.
          We_PRP next_RB examined_VBD whether_IN the_DT number_NN of_IN rolling_VBG and_CC
          firmly_RB adhered_VBD cells_NNS was_VBD quantified_VBN similarly_RB ._. We_PRP
          perfused_JJ neutrophils_NNS over_IN a_DT monolayer_NN of_IN activated_VBN EC_NNP at_IN
          1_CD ._. 5_CD dynes_NNS /_NN cm_NN 2_CD for_IN 10_CD mins_NNS ._. Each_DT min_NN we_PRP determined_VBD the_DT
          number_NN of_IN rolling_VBG and_CC firmly_RB adhered_VBD cells_NNS in_IN the_DT
          microscope_NN field_NN using_VBG each_DT of_IN the_DT three_CD chambers_NNS (_( Fig_NNP ._.
          1_LS B_NNP )_) ._. No_DT statistically_RB significant_JJ differences_NNS were_VBD seen_VBN
          between_IN the_DT classic_JJ ,_, single_JJ pass_NN GlycoTech_NNP or_CC
          recirculating_VBG designs_NNS ._. These_DT experiments_NNS were_VBD performed_VBN
          with_IN 0_CD ._. 02_CD "_'' ID_NNP tubing_VBG ,_, since_IN similar_JJ experiments_NNS with_IN
          0_CD ._. 01_CD "_'' ID_NNP tubing_VBG had_VBN bubbles_NNS in_IN the_DT line_NN that_WDT stripped_VBD the_DT
          neutrophils_NNS off_IN the_DT EC_NNP surface_NN periodically_RB (_( data_NNS not_RB
          shown_VBN )_) ._. This_DT occurred_VBD even_RB after_IN de-gasing_JJ the_DT perfusion_NN
          buffer_NN overnight_JJ ._. Although_IN not_RB proven_VBN ,_, we_PRP think_VBP this_DT is_VBZ
          likely_JJ due_NN to_TO small_JJ difference_NN between_IN the_DT ID_NNP of_IN the_DT
          tubing_VBG and_CC the_DT connecting_VBG ports_NNS that_WDT allows_VBZ for_IN slow_JJ
          accumulation_NN of_IN bubbles_NNS that_WDT periodically_RB release_NN ,_,
          flowing_VBG over_IN ,_, and_CC destroying_VBG the_DT monolayer_NN ._.
          Finally_RB ,_, we_PRP calculated_VBD the_DT rolling_VBG velocity_NN in_IN the_DT
          different_JJ chambers_NNS (_( Table_NNP 2_LS )_) ._. Neutrophils_NNP were_VBD perfused_JJ
          over_IN cell_NN monolayers_NNS expression_NN E-_NNP or_CC P-_NNP selectin_NN and_CC the_DT
          rolling_VBG velocities_NNS calculated_VBN ._. The_DT selectins_NNS are_VBP a_DT family_NN
          of_IN molecules_NNS on_IN which_WDT neutrophils_NNS will_MD roll_VB but_CC not_RB
          firmly_RB adhere_VB [_NN 20_CD ]_NN ._. Table_NNP 2_CD shows_VBZ that_IN significant_JJ
          differences_NNS in_IN rolling_VBG velocities_NNS of_IN neutrophils_NNS were_VBD
          seen_VBN on_IN E-_NNP versus_CC P-_NNP selectin_NN coated_JJ surfaces_VBZ in_IN agreement_NN
          with_IN previous_JJ observations_NNS ._. However_RB ,_, statistically_RB
          significant_JJ differences_NNS in_IN the_DT rolling_VBG velocities_NNS on_IN
          cellular_JJ surfaces_VBZ with_IN E-_NNP or_CC P-_NNP selectin_NN were_VBD not_RB observed_VBN
          regardless_RB of_IN flow_NN chamber_NN design_NN ._.
          Although_IN the_DT recirculation_NN design_NN may_MD suggest_VB that_IN the_DT
          neutrophils_NNS pass_VBP over_IN the_DT cell_NN monolayer_NN several_JJ times_NNS ,_,
          the_DT volumes_NNS and_CC perfusion_NN rates_NNS suggest_VBP otherwise_RB ._. For_IN
          instance_NN ,_, the_DT recirculating_VBG design_NN has_VBZ a_DT dead_JJ volume_NN of_IN
          850_CD μl_NN ._. In_IN a_DT 10_CD min_NN experiment_NN at_IN 1_CD ._. 5_CD dynes_NNS /_NN cm_NN 2_CD ,_, fluid_NN
          is_VBZ perfused_JJ at_IN 75_CD μl_NN /_NN min_NN for_IN a_DT total_NN of_IN 750_CD μl_NN or_CC only_RB
          88_CD %_NN of_IN the_DT volume_NN ,_, suggesting_VBG that_IN the_DT flowing_VBG
          neutrophils_NNS do_VBP not_RB pass_VB over_IN the_DT monolayers_NNS more_RBR than_IN
          once_RB ._. Finally_RB ,_, although_IN gap_NN height_NN of_IN the_DT chamber_NN may_MD
          also_RB be_VB varied_VBN to_TO reduce_VB the_DT volumes_NNS ,_, we_PRP employed_VBN the_DT
          narrowest_JJS gasket_NN currently_RB available_JJ for_IN the_DT Glycotech_NNP
          chamber_NN (_( 127_CD μm_NN )_) ._.
        
      
      
        Conclusions_NNP
        We_PRP have_VBP shown_VBN that_IN alterations_NNS in_IN the_DT configuration_NN of_IN
        flow_NN chambers_NNS can_MD dramatically_RB reduce_VB reagent_NN and_CC cellular_JJ
        requirements_NNS ._. These_DT modifications_NNS do_VBP not_RB adversely_RB effect_VB
        quantification_NN ._. In_IN the_DT past_NN ,_, it_PRP has_VBZ not_RB been_VBN feasible_JJ to_TO
        study_VB cell_NN populations_NNS that_WDT were_VBD represented_VBN at_IN less_JJR than_IN
        2_CD %_NN of_IN peripheral_JJ blood_NN leukocytes_NNS such_JJ as_IN basophils_NNS ,_,
        eosinophils_NNS ,_, or_CC some_DT lymphocyte_NN subsets_NNS ._. For_IN instance_NN ,_, 100_CD
        ml_NN of_IN blood_NN yields_NNS only_RB ~_NN 6_CD ×_NN 10_CD 5_CD basophils_NNS [_NN 17_CD ]_NN ._. This_DT
        number_NN of_IN basophils_NNS was_VBD not_RB sufficient_JJ for_IN studies_NNS in_IN the_DT
        classic_JJ chamber_NN ._. With_IN these_DT modifications_NNS in_IN this_DT report_NN ,_, 4_CD
        experiments_NNS can_MD be_VB performed_VBN Reductions_NNP in_IN reagent_NN
        requirements_NNS proportional_JJ to_TO those_DT of_IN cellular_JJ needs_VBZ also_RB
        occur_VB in_IN with_IN the_DT modifications_NNS employed_VBN in_IN this_DT report_NN ,_,
        since_IN the_DT modifications_NNS primarily_RB decrease_VBP volume_NN
        requirements_NNS ._. We_PRP have_VBP also_RB configured_JJ an_DT injection_NN port_NN in_IN
        the_DT single_JJ pass_NN GlycoTech_NNP chamber_NN configuration_NN ,_, allowing_VBG
        for_IN observation_NN of_IN the_DT rapid_JJ effects_NNS of_IN use_NN of_IN soluble_JJ
        factors_NNS ._. Thus_RB ,_, small_JJ molecules_NNS such_JJ as_IN chemokines_NNS ,_, peptides_NNS
        or_CC non-peptide_JJ organic_JJ compounds_NNS that_WDT previously_RB would_MD be_VB
        prohibitively_RB expensive_JJ to_TO study_VB can_MD now_RB be_VB studied_VBN ._. For_IN
        instance_NN ,_, 10_CD mg_NN of_IN a_DT decapeptide_NN commercially_RB produced_VBD for_IN
        approximately_RB $_$ 1000_CD ._. 00_CD and_CC used_VBN at_IN a_DT concentration_NN of_IN 1_CD mM_NN
        would_MD require_VB 6_CD ._. 6_CD mg_NN peptide_NN /_NN experiment_NN at_IN a_DT approximate_JJ
        cost_NN of_IN $_$ 660_CD /_NN experiment_NN while_IN the_DT recirculating_VBG chamber_NN
        with_IN 0_CD ._. 02_CD "_'' ID_NNP tubing_VBG requires_VBZ 0_CD ._. 94_CD mg_NN at_IN cost_NN of_IN
        $_$ 93_CD ._. 50_CD /_NN experiment_NN ,_, making_VBG large_JJ number_NN of_IN experiments_NNS
        affordable_JJ ._.
      
      
        Material_NNP and_CC Methods_NNP
        
          Neutrophil_NNP isolation_NN and_CC cell_NN culture_NN
          Human_NNP umbilical_JJ vein_NN endothelial_NN cell_NN (_( EC_NNP )_) cultures_NNS
          were_VBD purchased_VBN (_( Clontech_NNP ,_, Palo_NNP Alto_NNP ,_, CA_NNP )_) and_CC maintained_VBN
          at_IN 30_CD -_: 80_CD %_NN confluency_NN to_TO ensure_VB high_JJ viability_NN ._. Chinese_NNP
          Hamster_NNP Ovary_NNP (_( CHO_NNP )_) cells_NNS expressing_VBG human_JJ E-_NNP or_CC
          P-_NNP selectin_NN have_VBP been_VBN previously_RB described_VBN [_NN 6_CD 13_CD ]_NN ._.
          Cells_NNP were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP in_IN an_DT air_NN /_NN 5_CD %_NN CO_NNP 
          2_CD atmosphere_NN ._. Neutrophils_NNP were_VBD
          isolated_VBN as_RB previously_RB described_VBD in_IN detail_NN from_IN
          peripheral_JJ blood_NN isolated_VBN by_IN venipuncture_NN from_IN normal_JJ
          donors_NNS [_NN 6_CD 13_CD ]_NN ._.
        
        
          Parallel_JJ plate_NN flow_NN chamber_NN apparatus_NN configuration_NN
          and_CC modifications_NNS
          Two_CD flow_NN chambers_NNS with_IN parallel_JJ plate_NN geometry_NN were_VBD
          used_VBN (_( Fig_NNP ._. 1_LS Aand_NNP 1_CD B_NNP )_) ._. Both_DT flow_NN chambers_NNS consist_VBP of_IN :_: (_( 1_LS )_)
          base_NN plate_NN with_IN an_DT entrance_NN and_CC exit_NN port_NN through_IN which_WDT
          cells_NNS and_CC media_NNS are_VBP perfused_JJ ,_, (_( 2_LS )_) a_DT glass_NN or_CC plastic_NN
          slide_NN plate_NN on_IN which_WDT the_DT substrate_NN or_CC cellular_JJ monolayer_NN
          is_VBZ placed_VBN ,_, (_( 3_LS )_) a_DT gasket_NN that_IN controls_VBZ the_DT chamber_NN
          diameter_NN ,_, and_CC (_( 4_LS )_) a_DT vaccum_NN outlet_NN so_IN that_IN the_DT apparatus_NN
          can_MD be_VB held_VBN in_IN place_NN ._. The_DT sizes_NNS of_IN these_DT chambers_NNS and_CC
          their_PRP$ components_NNS are_VBP summarized_VBD in_IN Fig_NNP ._. 1_LS ._. The_DT first_JJ
          parallel_JJ plate_NN had_VBD the_DT identical_JJ dimensions_NNS as_IN described_VBN
          by_IN Lawrence_NNP et_CC al_NN [_NN 7_CD ]_NN and_CC was_VBD kindly_RB provided_VBN by_IN Dr_NNP ._.
          Lawrence_NNP (_( University_NNP of_IN Virginia_NNP )_) ._. The_DT second_JJ chamber_NN was_VBD
          purchased_VBN from_IN GlycoTech_NNP (_( Product_NN number_NN 31_CD -_: 001_CD ,_,
          Rockville_NNP ,_, MD_NNP )_) ._. The_DT GlycoTech_NNP chamber_NN was_VBD tested_VBN in_IN two_CD
          different_JJ configurations_NNS ,_, single-pass_JJ configuration_NN and_CC a_DT
          re-circulating_JJ configuration_NN ._. A_DT syringe_NN pump_NN (_( Harvard_NNP
          Apparatus_NNP ,_, Model_NNP 22_CD ,_, Cambridge_NNP ,_, MA_NNP )_) was_VBD employed_VBN in_IN the_DT
          single_JJ pass_NN configuration_NN and_CC a_DT peristaltic_JJ pump_NN (_( Harvard_NNP
          Apparatus_NNP ,_, Model_NNP 66_CD )_) was_VBD used_VBN in_IN the_DT recirculating_VBG
          configuration_NN ._. Internal_NNP tubing_VBG diameter_NN is_VBZ indicated_VBN in_IN
          the_DT text_NN ._. The_DT components_NNS of_IN each_DT configuration_NN were_VBD set_VBN
          up_RP to_TO minimize_VB tubing_VBG ,_, and_CC the_DT volume_NN requirements_NNS
          determined_VBN empirically_RB by_IN measuring_VBG the_DT volume_NN needed_VBN to_TO
          fill_VB the_DT apparatus_NN ._. A_DT chamber_NN was_VBD placed_VBN on_IN the_DT stage_NN of_IN
          an_DT inverted_JJ microscope_NN (_( Olympus_NNP ,_, NY_NNP )_) ._. A_DT CCD_NNP camera_NN (_( Vicon_NNP
          VC_NNP 240_CD ,_, Albuquerque_NNP ,_, NM_NNP )_) enabled_VBD recording_NN of_IN all_DT events_NNS
          in_IN the_DT video_NN field_NN by_IN a_DT Toshiba_NNP KV-_NNP 7168_CD A_DT recorder_NN (_( ADI_NNP ,_,
          Albuquerque_NNP ,_, NM_NNP )_) ._. The_DT recorded_VBN images_NNS were_VBD analyzed_VBN using_VBG
          NIH_NNP Image_NN 1_CD ._. 61_CD software_NN (_( available_JJ via_IN download_NN at_IN
          http_NN :_: rsb_NN ._. info_NN ._. nih_NN ._. gov_NN /_NN nih-image_JJ )_) ._.
        
        
          Parallel_JJ plate_NN flow_NN chamber_NN analysis_NN
          Cellular_NNP events_NNS in_IN the_DT parallel_JJ plate_NN flow_NN chamber_NN
          were_VBD enumerated_JJ as_IN previously_RB described_VBD [_NN 6_CD 16_CD ]_NN ._.
          Briefly_NNP ,_, Neutrophils_NNP are_VBP perfused_JJ over_IN EC_NNP or_CC CHO_NNP cell_NN
          monolayers_NNS at_IN defined_VBN shear_NN forces_NNS as_IN indicated_VBN in_IN text_NN
          in_IN the_DT parallel_JJ plate_NN flow_NN chamber_NN ._. EC_NNP are_VBP treated_VBN with_IN
          media_NNS alone_RB or_CC media_NNS containing_VBG a_DT potent_JJ activator_NN ,_,
          lipopolysaccharide_NN (_( LPS_NNP )_) at_IN 5_CD μg_NN /_NN ml_NN for_IN 4_CD h_NN ,_, washed_VBN ,_, and_CC
          placed_VBD in_IN a_DT parallel_JJ plate_NN flow_NN chamber_NN ._.
          The_DT entire_JJ period_NN of_IN leukocyte_NN perfusion_NN was_VBD
          videotaped_JJ under_IN phase-contrast_JJ microscopy_NN ._. All_DT
          experiments_NNS were_VBD recorded_VBN with_IN a_DT CCD_NNP video_NN camera_NN and_CC
          recorder_NN ._. Videotaped_NNP data_NNS frames_NNS were_VBD digitized_JJ for_IN data_NNS
          analysis_NN ._. Four_CD quantities_NNS were_VBD measured_VBN in_IN the_DT analysis_NN :_:
          the_DT total_JJ number_NN of_IN accumulated_VBN cells_NNS ,_, the_DT number_NN of_IN
          rolling_VBG cells_NNS ,_, the_DT number_NN of_IN firmly_RB arrested_VBN cells_NNS ,_, and_CC
          the_DT rolling_VBG velocity_NN ._. The_DT total_JJ number_NN of_IN accumulated_VBN
          cells_NNS was_VBD determined_VBN from_IN videotape_NN at_IN each_DT min_NN for_IN 10_CD
          min_NN by_IN analysis_NN of_IN 8_CD -_: 10_CD random_JJ fields_NNS (_( 20_CD X_NNP phase-contrast_JJ
          objective_NN )_) ._. Leukocytes_NNP were_VBD considered_VBN firmly_RB adherent_NN
          after_IN 15_CD s_VBZ of_IN stable_JJ contact_NN with_IN the_DT monolayer_NN ._. Rolling_NNP
          cells_NNS were_VBD easily_RB visualized_JJ since_IN they_PRP traveled_VBD more_RBR
          slowly_RB than_IN free-flowing_JJ cells_NNS ._. Rolling_NNP velocities_NNS were_VBD
          measured_VBN for_IN all_DT cells_NNS in_IN two_CD to_TO five_CD fields_NNS of_IN view_NN for_IN
          each_DT experiment_NN ._. Results_NNS are_VBP presented_VBN as_IN averages_NNS ._.
          Images_NNP were_VBD recorded_VBN on_IN a_DT time-lapse_JJ videocassette_NN
          recorder_NN at_IN real_JJ time_NN and_CC played_VBD back_RB at_IN 9_CD -_: fold_VB slower_JJR
          speed_NN ._. The_DT tape_NN was_VBD paused_VBD to_TO mark_VB the_DT location_NN of_IN cells_NNS ,_,
          and_CC the_DT distance_NN that_IN the_DT center_NN of_IN individual_JJ cells_NNS
          moved_VBD was_VBD measured_VBN 2_CD to_TO 4_CD s_VBZ later_RB ._.
        
      
    
  
